TRIM28 and central nervous system cancer: Considering that we have previously found that TRIM28 expression in a normal brain is significantly lower compared to GB tissue expression as well as lower-grade gliomas [29], the therapeutic administration of the anti-TRIM28 nanobody seems reasonable, especially since it shows the greatest effect on the invasive GSCs.